← Back to all trials
Active Not Recruiting
NCT07259811
Vertebral Augmentation Using VCFix Spinal System in Stand-alone Configuration
Conditions: Vertebral Compression Fracture
Sex: All
Ages: 22 Years – 85 Years
Healthy volunteers: No
Phase: NA
Enrollment: 10
Sponsor: Amber Implants B.V.
Location: Wilhelmsburger Krankenhaus Groβ-Sand Hamburg
Summary
This study will review the safety and possibility of the VCFix Spinal System. This is a proof-of-concept study and an initial review of the surgical procedure and how well the VCFix device works, to who that the VCFix is safe and works well in early testings, so that a larger safety study can be done later to help get CE approval. The VCFix Spinal System will be used in its independent setup, within its planned use for treatment of vertebral compression fracture. It's designed to be a small early study to test safety and see if the treatment idea is possible, with one group and no blinding. Two hospitals in EU will enroll in total 10 participants with a single vertebral fracture that will undergo the same surgery.
The main test goals are: how successful the access creation of the vertebral body is using the VCFix Preparation kit according to the provided instructions, how successful the positioning of the VCFix implant is by using the VCFix Implantation kit according to the provided instructions, and how successful the fracture reduction by expanding the VCFix implant according to the provided instructions. The main safety goal is: number of device-/procedure-related major side effects through 30 days after the initial procedure.
Participant enrollment will last around 12 months. Each participant will be followed for 2 years after the implantations. All side effects related to the spine will be documented throughout the study.
Eligibility Criteria
Inclusion Criteria:
* Male or Female between 22 and 85 years of age
* One (single) vertebral fracture which meets all the following criteria:
* Type A fractures as defined by the AO spine classification (compression injuries)1
* Vertebral fracture located in the thoracic and lumbar regions of the spine
* Fracture age \ 5
* Pain due to any other condition that requires daily narcotic medication
* Pre-existing neurological deficit, radiculopathy or myelopathy
* Significant clinical comorbidity that the enrolling physician considers may either contraindicate surgery or interfere with long-term data collection or follow-up
* Pre-existing conditions such as:
* Allergy to any components of the device/instruments used during the procedure or to PMMA bone cement
* Active or incompletely treated infection of the vertebral column or active systemic infection, including unresolved urinary tract infection
* Irreversible coagulopathy or bleeding disorder
* Uncontrolled diabetes (HbA1c \>8%)
* Severe cardiopulmonary deficiencies
* Contraindications to MRI or radionuclide bone scan
* Concurrent participation in any other clinical study for which the primary outcomes are not achieved
* A life expectancy less than the study duration or undergoing palliative care
* Patient non-ambulatory prior to fracture
* Spondylolisthesis \>Grade 1 at target vertebral body(s)
* Local kyphotic angle \>30°
* Any underlying systemic bone disease other than osteoporosis (e.g., osteomalacia, osteogenesis imperfect, Paget's disease, etc.)
* The patient has pain based on clinical diagnosis of herniated nucleus pulposus or severe spinal stenosis (progressive weakness or paralysis)
* Any evidence of substance use disorder (alcohol, drugs)
* Ongoing long-term steroid therapy (steroid dose ≥30 mg /day for \> 3 months)
* The patient is currently on anti-cancer therapy or anti-HIV therapy
* Patient known to be involved in medical litigation including Workmen's Compensation prior to the surgery
* Pregnancy or patients with child-bearing potential who do not accept taking contraception throughout the study duration
* Patients who require anterior stabilisation
Source: ClinicalTrials.gov (NCT07259811). StuddyBuddy aggregates publicly available trial information.